|
BioRestorative Therapies, Inc. (BioRestorative), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced that the Israel Patent Office has issued a Notice of Allowance for a new patent application (Israeli Patent Appl. No. 287557) covering several fundamental aspects of the company’s allogeneic, off-the-shelf ThermoStem platform.
This, the 14th international patent to issue outside of the US for BioRestorative’s ThermoStem technology platform, covers non-naturally occurring three-dimensional brown adipose derived stem cell (BADSC) aggregates; an encapsulation system comprising the non-naturally occurring three-dimensional brown adipose derived stem cell aggregates; a method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate; and a method of treating a patient with a disorder.
“We believe that our ThermoStem -based BADSCs hold tremendous promise to deliver a superior efficacy and tolerability profile over GLP-1 drugs,” said Lance Alstodt, BioRestorative’s chief executive officer. “This latest patent issuance demonstrates our strong commitment to protecting the innovation of our ThermoStem programme and the significant potential commercial opportunity that it represents for ourselves and any current and/or future potential licensing partners. And, given Israel’s global prominence in stem cell research, we are particularly excited by this latest patent issuance.”
In May 2024, BioRestorative revealed the development of a novel exosome-based biologic program targeting obesity, advising that the company plans to initiate the formal US Food and Drug Administration (FDA) process for this ThermoStem-based therapeutic candidate by filing a Drug Master File (DMF). On the heels of that announcement, BioRestorative reported that it had begun to engage in substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a potential license of BioRestorative’s allogeneic, off-the-shelf ThermoStem metabolic intellectual property. Those discussions are continuing; however, no assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise.
BioRestorative develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its two core clinical development programmes relate to the treatment of disc/spine disease and metabolic disorders, and the company have also recently begun offering biocosmeceutical products.
|